SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that its breast cancer risk genetic test, BRCATrue, was included in Inc. magazine’s Coolest Products of the Inc. 500. The genetic test was ranked in the top 12 products from 5000 companies across the nation. View the full list here.
“We are honored to be included among incredibly innovative products and forward-thinking companies,” said Jim Plante, Pathway Genomics’ founder and CEO. “Our mission is to provide the most accurate and actionable genetic testing results to physicians and their patients.”
Earlier in the year, Inc. magazine ranked Pathway Genomics No. 173, with a three-year growth rate of 2,415.5%, on its 33rd annual Inc. 500|5000, an exclusive ranking of the nation's fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy — America’s independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other well-known names gained early exposure as members of the Inc. 500|5000.
As a government-accredited clinical laboratory, Pathway Genomics offers a comprehensive line of actionable genetic tests that provides physicians with a patient’s genetic indicators for cancer, cardiac conditions, inherited diseases, nutrition and exercise response, and drug response for medications, specifically those used in pain management and mental health.
About Pathway Genomics Corporation
As a CLIA and CAP accredited clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.